Exosomal formulation enhances therapeutic response of celastrol against lung cancer

Experimental and Molecular Pathology

Volumn 101, Issue 1, 2016, Pages 12-21

  Aqil, Farrukh ^a,b   Kausar, Hina ^b   Agrawal, Ashish Kumar ^b   Jeyabalan, Jeyaprakash ^b   Kyakulaga, Al Hassan ^a   Munagala, Radha ^a,b   Gupta, Ramesh ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Celastrol; Drug delivery; Lung cancer; Milk derived exosomes

Indexed keywords

CELASTROL; CHAPERONE; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROTEIN BAX; PROTEIN BCL 2; PROTEIN PERK; UNCLASSIFIED DRUG; TRIPTERINE; TRITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; ENCAPSULATION; ENDOPLASMIC RETICULUM STRESS; EXOSOME; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MITOSIS INHIBITION; MOUSE; NONHUMAN; TUMOR XENOGRAFT; A-549 CELL LINE; ANIMAL; APOPTOSIS; BOVINE; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY;

A549 CELLS; ANIMALS; APOPTOSIS; CATTLE; CELL CYCLE; CELL PROLIFERATION; ENDOPLASMIC RETICULUM STRESS; EXOSOMES; FEMALE; LUNG NEOPLASMS; MICE, NUDE; NF-KAPPA B; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84973293346     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2016.05.013     Document Type: Article

References (44)

1. Allison A.C., et al. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2001, 25:1341-1357.
2. Aqil F., et al. Multi-layer polymeric implants for sustained release of chemopreventives. Cancer Lett. 2012, 326:33-40.
3. Aqil F., et al. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 2013, 334:133-141.
4. Chang F.R., et al. Antitumor agents. 228. Five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii. J. Nat. Prod. 2003, 66:1416-1420.
5. Chen Y., et al. Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int. J. Nanomedicine 2012, 7:3023-3032.
6. Choi J.Y., et al. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy. Acta Biomater. 2016.
7. Cragg G.M., Newman D.J. Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta 2013, 1830:3670-3695.
8. Feng L., et al. ER stress-mediated apoptosis induced by celastrol in cancer cells and important role of glycogen synthase kinase-3beta in the signal network. Cell Death Dis. 2013, 4:e715.
9. Haney M.J., et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J. Control. Release 2015, 207:18-30.
10. Hoesel B., Schmid J.A. The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer 2013, 12:86.
11. Huang Y., et al. Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol. Anti-Cancer Drugs 2012, 23:515-524.
12. Jang S.Y., et al. Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor alpha. Cancer Lett. 2011, 300:57-65.
13. Jiang Q.W., et al. Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine. Oncotarget 2015, 6:32790-32804.
14. Jin H.Z., et al. Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-kappaB activation and NO production. J. Nat. Prod. 2002, 65:89-91.
15. Ju S.M., et al. Celastrol ameliorates cytokine toxicity and pro-inflammatory immune responses by suppressing NF-kappa B activation in RINm5F beta cells. BMB Rep. 2015, 48:172-177.
16. Kannaiyan R., et al. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 2011, 303:9-20.
17. Kausar H., et al. Berry anthocyanidins synergistically suppress growth and invasive potential of human non-small-cell lung cancer cells. Cancer Lett. 2012, 325:54-62.
18. Kausar H., et al. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. Cancer Lett. 2013, 332:35-45.
19. Kim M.S., et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomed.: Nanotechnol., Biol. Med. 2016, 12:655-664.
20. Lai C.P.K., Breakefield X.O. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front. Physiol. 2012, 3.
21. Li X., et al. Unfolded protein response in cancer: the physician's perspective. J. Hematol. Oncol. 2011, 4:8.
22. Li Z., et al. Antitumor activity of celastrol nanoparticles in a xenograft retinoblastoma tumor model. Int. J. Nanomedicine 2012, 7:2389-2398.
23. Munagala R., et al. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer. Cancer Lett. 2015, 356:536-546.
24. Munagala R., et al. Bovine milk-derived exosomes for drug delivery. Cancer Lett. 2016, 371:48-61.
25. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75:311-335.
26. Ni H.W., et al. NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis. PLoS One 2014, 9.
27. Niemela E., et al. Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells. Eur. J. Pharm. Biopharm. 2015, 96:11-21.
28. Pahl H.L., Baeuerle P.A. A novel signal-transduction pathway from the endoplasmic-reticulum to the nucleus is mediated by transcription factor Nf-kappa-B. EMBO J. 1995, 14:2580-2588.
29. Peng B., et al. HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol. Cancer 2010, 9.
30. Rajendran P., et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev. Res. 2012, 5:631-643.
31. Salminen A., et al. Celastrol: molecular targets of Thunder God Vine. Biochem. Biophys. Res. Commun. 2010, 394:439-442.
32. Sanna V., et al. Nanoencapsulation of natural triterpenoid celastrol for prostate cancer treatment. Int. J. Nanomedicine 2015, 10:6835-6846.
33. Shore G.C., et al. Signaling cell death from the endoplasmic reticulum stress response. Curr. Opin. Cell Biol. 2011, 23:143-149.
34. Siegel R.L., et al. Cancer statistics, 2016. Ca-a Cancer J. Clin. 2016, 66:7-30.
35. Song J., et al. Formulation and evaluation of celastrol-loaded liposomes. Molecules 2011, 16:7880-7892.
36. Tang X., et al. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 2006, 107:2637-2646.
37. Tian Y.H., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35:2383-2390.
38. Toffoli G., et al. Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. Nanomedicine 2015, 10:2963-2971.
39. Yang H.J., et al. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66:4758-4765.
40. Yu Y., et al. Celastrol inhibits inflammatory stimuli-induced neutrophil extracellular trap formation. Curr. Mol. Med. 2015, 15:401-410.
41. Zhang T., et al. Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J. Biol. Chem. 2009, 284:35381-35389.
42. Zhang X.W., et al. Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation. J. Pharm. Sci. 2014, 103:1711-1719.
43. Zhu H., et al. Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells. PLoS One 2012, 7:e52333.
44. Zhuang X.Y., et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 2011, 19:1769-1779.